Estrogen Patch Shortage Threatens Menopause Care

A widespread shortage of estrogen patches, a common treatment for menopause and perimenopause symptoms, is causing significant concern among physicians and patients. This supply issue affects nearly half of women utilizing hormone replacement therapy, leading some to ration their medication or cease treatment entirely. The situation has prompted calls for increased FDA intervention to address manufacturing capacity, which some experts believe is not keeping pace with demand.

Historically, the use of hormone replacement therapy declined significantly after a 2002 study linked it to increased health risks. However, recent evidence has clarified these risks, leading to the removal of a black-box warning label last fall. This change has encouraged more women to seek treatment, but manufacturers suggest this increased use, rather than a fundamental surge in demand, is straining current production levels. Some companies have ceased production, while others are working to boost global capacity, though creating these patches is a complex process.

Beyond symptom relief, estrogen therapy plays a crucial role in protecting against osteoporosis and positively impacting mood, memory, and libido. Alternative treatments like gels and creams are often more expensive and not consistently covered by insurance. Experts emphasize that the problem lies not just with increased demand but also with manufacturing limitations and the broader insurance industry's influence on drug access. Advocacy for better menopause care and coverage is growing, with legislative efforts and increased provider certifications aiming to improve the landscape.